Surufatinib in combination with toripalimab in patients with advanced neuroendocrine carcinoma: Results from a multicenter, open-label, single-arm, phase II trial.

Lin Shen,Xianjun Yu,Ming Lu,Xing Zhang,Ying Cheng,Yanqiao Zhang,Zhiping Li,Jianming Xu,De Sheng Weng,Chunjiao Wu,Yue Ma,Ke Cheng,Wen-Quan Wang,Heli Gao,Yi Li,Jinghong Zhou,Haiyan Shi,Panfeng Tan,Weiguo Su

Surufatinib in combination with toripalimab in patients with advanced neuroendocrine carcinoma: Results from a multicenter, open-label, single-arm, phase II trial.

2021

Lin Shen
Xianjun Yu
Ming Lu
Xing Zhang
Ying Cheng
Yanqiao Zhang
Zhiping Li
Jianming Xu
De Sheng Weng
Chunjiao Wu
Yue Ma
Ke Cheng
Wen-Quan Wang
Heli Gao
Yi Li
Jinghong Zhou
Haiyan Shi
Panfeng Tan
Weiguo Su

e16199Background: Patients with advanced neuroendocrine carcinoma (NEC) have a poor prognosis and limited treatment option after first-line treatment. Surufatinib, a multi-kinase inhibitor of VEGFR...

Keywords:

neuroendocrine carcinoma
treatment options
in patient
VEGF receptors
Oncology
Medicine
open label
Internal medicine
poor prognosis

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations